key: cord-0704865-rwb1cj06 authors: Hidalgo Filho, Cassio Murilo Trovo; Dalessandro Adamo, Denise Silvia Mattioli; Lopes, Camila Mendonça; Martin, Eloísa Moreira title: Thrombotic thrombocytopenic purpura associated with COVID-19 in a pediatric patient: case report date: 2021-04-08 journal: Hematol Transfus Cell Ther DOI: 10.1016/j.htct.2021.02.003 sha: 38c379edcd02c9ad49f29e4462454a8099acc61b doc_id: 704865 cord_uid: rwb1cj06 nan The coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is a global pandemic with more than 100 million recorded cases to the present date (1). By mechanisms that are still poorly understood, this infection is associated with several hematological complications. Initial data show that such events are the result of the state of hypercoagulability caused by the immune response to infection by SARS-CoV-2 (2). Autoimmune diseases have been reported in association with this pandemic disease, among which we find in the literature few reports of COVID-19 associated with thrombotic thrombocytopenic purpura (TTP) (3) (4) (5) . TTP is characterized by systemic microvascular thrombosis with platelet aggregation. It typically presents with hemolytic anemia, thrombocytopenia, renal dysfunction, fever and neurological involvement, to varying degrees. This condition is associated with deficiency of the enzyme responsible for the cleavage of the von Willebrand factor, disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). The reduction in the ADAMTS13 activity (< 10%), together with the presence of inhibitory anti-ADAMTS13 autoantibodies, suggests acquired TTP (6) . Infections are often associated as triggering factors for the initial manifestation of autoimmune thrombotic purpura, as well as with exacerbations of the disease (7). Our case reports a rare association of acquired TTP in a pediatric patient with recent SARS-CoV-2 infection. A 14-year-old female patient, who had a past medical history of depression was transferred to our hospital in August 2020 due to headache and altered level of consciousness. The patient had past symptoms of fever (body temperature 38°C), cough, dyspnea, fatigue and malaise for approximately 11 days, that resolved spontaneously about twenty days before hospitalization and during the same period her parents had similar symptoms, but received no medical care. The initial laboratory screening (Table 1) Although the prognosis of the disease has improved considerably with the use of PEX, it remains a serious condition with a mortality rate of approximately 10%, despite the therapy (8, 9) . The patient in the case described was treated with daily sessions of plasma exchange and adjuvant systemic corticosteroids, as suggested in the literature, and despite the infectious complication, she recovered from the acute condition and received hospital discharge for follow-up (6) . Studies show that TTP has a high risk of relapse, especially during the first year of the disease and in patients with positive anti-ADAMTS13 inhibitors. The patient in the reported case can be considered at high risk for relapses, which are associated with greater morbidity and mortality (10) . Evidence shows that rituximab can be used to prevent relapse of the disease, especially in patients at high risk, as the report presented. However, it is not immediately available at our service, being used only in refractory cases. Other promising therapies described, such as n-acetylcysteine and recombinant ADAMTS13, were not used due to the good response to the initial treatment (9). (12) . There is currently no information about TTP leading to false-positive SARS-CoV-2 serological tests. The main limitation of this report is that there is not enough evidence in the literature to conclude that the acquired thrombotic thrombocytopenic purpura was caused by the immune response to SARS-CoV-2, which may be a case of chance due to the high prevalence of COVID-19. This report suggests that this pandemic infectious disease is one of several possible causes of acquired TTP. The immunological deregulation caused by late SARS-CoV-2 infection could have precipitated this hematological disorder. We believe that further studies should be published to confirm the existence of the causal factor between these two conditions. TTP should be suspected in the presence of characteristic signs and symptoms, such as thrombocytopenia, neurological symptoms and signs of hemolytic anemia with schistocytes in the peripheral blood smear, and treated promptly to reduce the risk of mortality. COVID-19 should be part of the investigation at the onset of TTP with no obvious cause, especially in the presence of respiratory symptoms and a compatible chest image. Johns Hopkins Coronavirus Resource Center COVID-19 and its implications for thrombosis and anticoagulation. Blood Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19 COVID-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case Dramatic presentation of acquired thrombotic thrombocytopenic purpura associated with COVID-19 Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers Pediatric thrombotic thrombocytopenic purpura Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura Are patients with systemic lupus erythematosus more prone to result false-positive for SARS-CoV2 serology?